Prelude's CEO, Dr. Kris Vaddi, asserts that the additional funding will boost the clinical development of PRT3789 and progress of the oral program. Further clinical results from PRT3789 and the initiation of their oral program are expected in second half of 2024.
The stock has a high risk of funding distress due to high cash expenditure relative to the company's market value. Increasing cash burn trajectory may require further capital raising, risking shareholder value dilution.
$Prelude Therapeutics(PRLD.US)$Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
$Prelude Therapeutics(PRLD.US)$@Tupack H McsnacksGood afternoon..just started investing, may I know to hold or exit for PRLD which has been heading downwards, your advice is deeply appreciated. Thanks
4
2
舉報
Mcsnacks H Tupack :
我會等一下。分析師上週五剛剛將其評級上調至買入。RSI目前為18,因此應該會有更多的投資者開始在這個價格買入
Prelude Therapeutics股票討論區
• $Ascendis Pharma A/S(ASND.US)$: BofA Securities Upgrades to Buy from Neutral - PT $161 (from $148)
• $GoodRx(GDRX.US)$: Baird Upgrades to Outperform from Neutral - PT $17
• $美國固安捷(GWW.US)$: Atlantic Equities Upgrades to Overweight from Neutral - PT $580 (from $520)
• $哈特蘭快遞(HTLD.US)$: Morgan Stanley Upgrades to Equalweight from Underweight - PT $16
• $美國美盛(MOS.US)$: Goldman Sachs Upgrades to Buy from Neutral - PT $83
• $Northern Oil & Gas(NOG.US)$: Johnson ...
2. $Osmotica Pharmaceuticals PLC(OSMT.US)$
3. $Oric Pharmaceuticals(ORIC.US)$
(NOT FINANCIAL ADVICE)
Always Do Your DD
暫無評論